Back to Journals » Psoriasis: Targets and Therapy
![](https://www.dovepress.com/cr_data/cache/journal_image/121/cope/thumb_100_1000_100.jpg)
Psoriasis: Targets and Therapy
ISSN: 2230-326X
- View all (141)
- Volume 14, 2024 (8)
- Volume 13, 2023 (7)
- Volume 12, 2022 (22)
- Volume 11, 2021 (14)
- Volume 10, 2020 (8)
- Volume 9, 2019 (13)
- Volume 8, 2018 (12)
- Volume 7, 2017 (9)
- Volume 6, 2016 (15)
- Volume 5, 2015 (13)
- Volume 4, 2014 (5)
- Volume 3, 2013 (4)
- Volume 2, 2012 (10)
- Volume 1, 2011 (1)
Journal Articles:
- 141 records -
Effectiveness and Drug Survival of Ixekizumab and Secukinumab in Patients with Moderate to Severe Plaque Psoriasis: Real-World Data from Bucharest, Romania
Bucur S, Serban ED, Ileanu BV, Costache RS, Nicolescu AC, Constantin T, Costache DO, Constantin MM
Psoriasis: Targets and Therapy 2024, 14:79-86
Published Date: 25 June 2024
![Plain language summary](assets/img/article_icons/plain-language.png)
Burden of Herpes Zoster Among Patients with Psoriatic Arthritis in the United States
![](cr_data/cache/article_graphical_abstract/s430151/graphical_abstract.jpg)
Singer D, Thompson-Leduc P, Ma S, Gupta D, Cheng WY, Sendhil SR, Sundar M, Hagopian E, Stempniewicz N, Duh MS, Poston S
Psoriasis: Targets and Therapy 2024, 14:63-78
Published Date: 22 June 2024
The Perspective of Cannabidiol in Psoriasis Therapy
Stanescu AMA, Bejan GC, Balta MD, Andronic O, Toma C, Busnatu S
Psoriasis: Targets and Therapy 2024, 14:51-61
Published Date: 19 June 2024
Risk Factors for Psoriasis Flares: A Narrative Review
Potestio L, Lauletta G, Tommasino N, Portarapillo A, Salsano A, Battista T, Martora F, Megna M
Psoriasis: Targets and Therapy 2024, 14:39-50
Published Date: 30 May 2024
Perception and Impact of COVID-19 Pandemic in Psoriasis Patients: Data from the German PsoBest and the CoronaBest Registries
Valencia López MJ, Stephan B, Meineke A, Wolf S, Thaci D, Mrowietz U, Andrees V, Rustenbach SJ, Reich K, Thalmann L, Bogena H, Staubach P, von Kiedrowski RM, Augustin M
Psoriasis: Targets and Therapy 2024, 14:29-38
Published Date: 14 May 2024
Therapeutic Potential of Spesolimab-Sbzo in the Management of Generalized Pustular Psoriasis Flares in Adults: Evidence to Date
Rega F, Trovato F, Bortone G, Pellacani G, Richetta AG, Dattola A
Psoriasis: Targets and Therapy 2024, 14:23-27
Published Date: 15 March 2024
Experiences of Dermatologists and Patients Regarding Psoriasis and Its Connection to Psoriatic Arthritis in Saudi Arabia
Fatani MI, Al-homood I, Bedaiwi M, Al Natour S, Erdogan A, Alsharafi A, Attar SM
Psoriasis: Targets and Therapy 2024, 14:11-22
Published Date: 18 January 2024
![Thematic Series](assets/img/article_icons/thematic-series.png)
The Effects of Cardiometabolic Comorbidities on Biologic Treatment for Psoriasis with Respect to PASI Scores: A Qualitative Systematic Review
Osman A, Nigro A, Taylor AC, Saal R, Ormaza Vera A, Enos C
Psoriasis: Targets and Therapy 2024, 14:1-10
Published Date: 10 January 2024
The Skin Microbiome and Its Role in Psoriasis: A Review
Celoria V, Rosset F, Pala V, Dapavo P, Ribero S, Quaglino P, Mastorino L
Psoriasis: Targets and Therapy 2023, 13:71-78
Published Date: 26 October 2023
Management of Plaque Psoriasis in Adults: Clinical Utility of Tapinarof Cream
Spencer RK, Jin JQ, Elhage KG, Davis MS, Liao W, Bhutani T
Psoriasis: Targets and Therapy 2023, 13:59-69
Published Date: 25 October 2023
![Thematic Series](assets/img/article_icons/thematic-series.png)
Palmoplantar Pustulosis: A Systematic Review of Risk Factors and Therapies
Heidemeyer K, May Lee M, Cazzaniga S, Yawalkar N, Naldi L
Psoriasis: Targets and Therapy 2023, 13:33-58
Published Date: 22 September 2023
![Thematic Series](assets/img/article_icons/thematic-series.png)
Therapeutic Management of a Case of Severe Psoriasis Coexistent with Bullous Pemphigoid in the Elderly
Di Lernia V, Peccerillo F, Ficarelli E
Psoriasis: Targets and Therapy 2023, 13:27-31
Published Date: 22 August 2023
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature
Potestio L, Ruggiero A, Fabbrocini G, Martora F, Megna M
Psoriasis: Targets and Therapy 2023, 13:19-26
Published Date: 4 May 2023
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Safety and Efficacy of Covid-19 Vaccination in Patients Undergoing Biological Treatments for Psoriasis
Potestio L, Martora F, Fabbrocini G, Battista T, Megna M
Psoriasis: Targets and Therapy 2023, 13:11-18
Published Date: 12 April 2023
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Analysis of Drug Utilization in Patients with Psoriasis: A Real-World Retrospective Study Among the Italian Population
Perrone V, Losi S, Sabatino S, Mezzetti M, Dovizio M, Sangiorgi D, Degli Esposti L
Psoriasis: Targets and Therapy 2023, 13:1-9
Published Date: 2 March 2023
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Assessment of Vitamin D Level in Patients with Psoriasis and Its Correlation with Disease Severity: A Case–Control Study
Pokharel R, Agrawal S, Pandey P, Lamsal M
Psoriasis: Targets and Therapy 2022, 12:251-258
Published Date: 13 September 2022
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Towards Personalized Medicine in Psoriasis: Current Progress
Camela E, Potestio L, Ruggiero A, Ocampo-Garza SS, Fabbrocini G, Megna M
Psoriasis: Targets and Therapy 2022, 12:231-250
Published Date: 1 September 2022
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Therapeutic Inertia in the Management of Psoriasis: A Quantitative Survey Among Indian Dermatologists and Patients
Rajagopalan M, Dogra S, Godse K, Kar BR, Kotla SK, Neema S, Saraswat A, Shah SD, Madnani N, Sardesai V, Sekhri R, Varma S, Arora S, Kawatra P
Psoriasis: Targets and Therapy 2022, 12:221-230
Published Date: 25 August 2022
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Reducing the Risk of Developing Psoriatic Arthritis in Patients with Psoriasis
Gisondi P, Bellinato F, Maurelli M, Geat D, Zabotti A, McGonagle D, Girolomoni G
Psoriasis: Targets and Therapy 2022, 12:213-220
Published Date: 10 August 2022
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study
Megna M, Potestio L, Fabbrocini G, Ruggiero A
Psoriasis: Targets and Therapy 2022, 12:205-212
Published Date: 14 July 2022
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Efficacy and Safety of Anti-TNF Biosimilars for Psoriasis in Pediatric and Geriatric Populations: A 72-Week Real-Life Study
Megna M, Fornaro L, Potestio L, Luciano MA, Nocerino M, Delfino M, Guarino M, Fabbrocini G, Camela E
Psoriasis: Targets and Therapy 2022, 12:199-204
Published Date: 9 July 2022
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Psoriasis and Exercise: A Review
Yeroushalmi S, Hakimi M, Chung M, Bartholomew E, Bhutani T, Liao W
Psoriasis: Targets and Therapy 2022, 12:189-197
Published Date: 2 July 2022
Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management [Corrigendum]
Al-Janabi A, Yiu ZZN
Psoriasis: Targets and Therapy 2022, 12:187-188
Published Date: 1 July 2022
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Dimethyl Fumarate as Therapeutic Alternative in Moderate-to-Severe Psoriasis: Our Experience
Rosés Gibert P, de la Torre Gomar FJ, Saenz Aguirre A, Gimeno Castillo J, González Pérez R
Psoriasis: Targets and Therapy 2022, 12:177-185
Published Date: 29 June 2022
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Dietary Intervention and Supplements in the Management of Psoriasis: Current Perspectives
Chung M, Bartholomew E, Yeroushalmi S, Hakimi M, Bhutani T, Liao W
Psoriasis: Targets and Therapy 2022, 12:151-176
Published Date: 22 June 2022
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Comorbidity in Adult Psoriasis: Considerations for the Clinician
Daugaard C, Iversen L, Hjuler KF
Psoriasis: Targets and Therapy 2022, 12:139-150
Published Date: 10 June 2022
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge
Ruggiero A, Potestio L, Camela E, Fabbrocini G, Megna M
Psoriasis: Targets and Therapy 2022, 12:127-137
Published Date: 8 June 2022
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Comorbid Psoriasis and Metabolic Syndrome: Clinical Implications and Optimal Management
De Brandt E, Hillary T
Psoriasis: Targets and Therapy 2022, 12:113-126
Published Date: 25 May 2022
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Biologics Can Significantly Improve Dermatology Life Quality Index (DLQI) in Psoriatic Patients: A Systematic Review
de Ruiter CC, Rustemeyer T
Psoriasis: Targets and Therapy 2022, 12:99-112
Published Date: 24 May 2022
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Economic Burden of Generalized Pustular Psoriasis in Sweden: A Population-Based Register Study
Löfvendahl S, Norlin JM, Schmitt-Egenolf M
Psoriasis: Targets and Therapy 2022, 12:89-98
Published Date: 5 May 2022
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Updated Perspectives on Keratinocytes and Psoriasis: Keratinocytes are More Than Innocent Bystanders
Ortiz-Lopez LI, Choudhary V, Bollag WB
Psoriasis: Targets and Therapy 2022, 12:73-87
Published Date: 2 May 2022
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
The Efficacy and Tolerability of Turmeric and Salicylic Acid in Psoriasis Treatment
Draelos ZD
Psoriasis: Targets and Therapy 2022, 12:63-71
Published Date: 29 April 2022
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
An Open-Label, Randomized, Prospective, Comparative, Three-Arm Clinical Trial to Evaluate the Safety and Effectiveness of Apremilast with Three Different Titration Methods in Patients with Chronic Plaque Psoriasis in India
Viswanath V, Joshi P, Lawate P, Tare D, Dhoot D, Mahadkar N, Barkate H
Psoriasis: Targets and Therapy 2022, 12:53-61
Published Date: 22 April 2022
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
The Effect of Lifestyle Changes on Disease Severity and Quality of Life in Patients with Plaque Psoriasis: A Narrative Review
van Acht MR, van den Reek JMPA, de Jong EMGJ, Seyger MMB
Psoriasis: Targets and Therapy 2022, 12:35-51
Published Date: 9 April 2022
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Assessing and Improving Psychological Well-Being in Psoriasis: Considerations for the Clinician
Blackstone B, Patel R, Bewley A
Psoriasis: Targets and Therapy 2022, 12:25-33
Published Date: 25 March 2022
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Telemedicine and e-Health in the Management of Psoriasis: Improving Patient Outcomes – A Narrative Review
Havelin A, Hampton P
Psoriasis: Targets and Therapy 2022, 12:15-24
Published Date: 16 March 2022
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management
Al-Janabi A, Yiu ZZN
Psoriasis: Targets and Therapy 2022, 12:1-14
Published Date: 6 January 2022
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
The Use of Metrics in Daily Practice and the Perception of Psoriasis-Associated Comorbidities: Discrepancies Between Research and Real-World
Hillary T, Lambert J
Psoriasis: Targets and Therapy 2021, 11:169-175
Published Date: 21 December 2021
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Non-Alcoholic Fatty Liver Disease (NAFLD) in Patients with Psoriasis: A Review of the Hepatic Effects of Systemic Therapies
Balak DMW, Piaserico S, Kasujee I
Psoriasis: Targets and Therapy 2021, 11:151-168
Published Date: 7 December 2021
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
High-Throughput RNA Sequencing Reveals the Effect of NB-UVB Phototherapy on Major Inflammatory Molecules of Lesional Psoriasis
Vacharanukrauh P, Meephansan J, Tangtanatakul P, Soonthornchai W, Wongpiyabovorn J, Serirat O, Komine M
Psoriasis: Targets and Therapy 2021, 11:133-149
Published Date: 26 November 2021
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Efficacy of Brodalumab and Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis Who are Inadequate Responders to Ustekinumab: A Matching Adjusted Indirect Comparison
Hampton P, Borg E, Hansen JB, Augustin M
Psoriasis: Targets and Therapy 2021, 11:123-131
Published Date: 3 November 2021
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
The Use of Apremilast in Psoriasis: An Indian Perspective on Real-World Scenarios
Rajagopalan M, Dogra S, Saraswat A, Varma S, Banodkar P
Psoriasis: Targets and Therapy 2021, 11:109-122
Published Date: 14 August 2021
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Psoriasis and Cardiometabolic Diseases: The Impact of Inflammation on Vascular Health
Teklu M, Parel PM, Mehta NN
Psoriasis: Targets and Therapy 2021, 11:99-108
Published Date: 21 July 2021
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Key Signaling Pathways in Psoriasis: Recent Insights from Antipsoriatic Therapeutics
Ben Abdallah H, Johansen C, Iversen L
Psoriasis: Targets and Therapy 2021, 11:83-97
Published Date: 29 June 2021
An Association of Pediatric Psoriasis with Metabolic Syndrome in Thai Children: 20 Years Retrospective Study
Mhusakunchai P, Techasatian L
Psoriasis: Targets and Therapy 2021, 11:75-82
Published Date: 29 June 2021
![There is a lack of data for erythrodermic psoriasis although this subtype can be a dermatological emergency. The available and widespread experience has been summarized by the authors to provide a valuable background for individual treatment decisions.](assets/img/article_icons/noteworthy.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Updates on the Treatment of Erythrodermic Psoriasis
Lo Y, Tsai TF
Psoriasis: Targets and Therapy 2021, 11:59-73
Published Date: 9 June 2021
Effectiveness of IL-23 Inhibitor Guselkumab in Real-World Chinese Patients with Psoriasis During a 20-Week Period
Chan Y, Tong BSB, Ngan PY, Au CS
Psoriasis: Targets and Therapy 2021, 11:53-58
Published Date: 1 June 2021
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Association of HLA Alleles and HLA Haplotypes with Psoriasis, Psoriatic Arthritis and Disease Severity in a Miscegenated Population
Cassia FF, Cardoso JF, Porto LC, Ramos-e-Silva M, Carneiro S
Psoriasis: Targets and Therapy 2021, 11:41-51
Published Date: 10 May 2021
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Frequency of Health Care Resource Utilization and Direct Medical Costs Associated with Psoriatic Arthritis in a Rheumatic Care Center in Colombia
Santos-Moreno P, Gómez-De la Rosa F, Parra-Padilla D, Alvis-Zakzuk NJ, Alvis-Zakzuk NR, Carrasquilla-Sotomayor M, Valencia O, Alvis-Guzmán N
Psoriasis: Targets and Therapy 2021, 11:31-39
Published Date: 18 March 2021
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Phosphodiesterase-4 Inhibition in Psoriasis
Milakovic M, Gooderham MJ
Psoriasis: Targets and Therapy 2021, 11:21-29
Published Date: 17 March 2021